NCT06690281 2025-09-11
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
Clinical Trials
11 trialsNCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT04895046 2022-06-29
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04546828 2022-06-15
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
Phase 2 Withdrawn
NCT04479904 2021-06-22
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT03801499 2020-05-21
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Withdrawn
NCT00386516 2017-08-01
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT01501604 2015-09-17
BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01775280 2015-06-09
RESRAD
University of Zurich
Phase 2 Withdrawn
NCT00713687 2012-08-10
GemOx-PDT
Technical University of Munich
Phase 2 Withdrawn